Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Andela is Named a Select Tier Services Partner in the Claude Partner Network

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026
    Facebook X (Twitter) Instagram
    Egypt News HubEgypt News Hub
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Egypt News HubEgypt News Hub
    Home » Moderna begins Ebola vaccine trial amid DR Congo outbreak
    Health

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    August 5, 2026
    Facebook Twitter Pinterest LinkedIn Reddit WhatsApp Email

    NOVA SCOTIA, CANADA / RankWire.AI / – Moderna has started a Phase 1 trial of an experimental vaccine against Bundibugyo ebolavirus in Canada. The first participant received the mRNA-1469 vaccine on August 3 at a site in Truro, Nova Scotia. The trial comes as the virus continues spreading across several provinces in the Democratic Republic of the Congo. The World Health Organization has classified the outbreak as a public health emergency of international concern.

    Moderna begins Ebola vaccine trial amid DR Congo outbreak
    Moderna begins human testing of a Bundibugyo Ebola vaccine during the DR Congo outbreak.

    The study will operate at three Canadian sites and enroll about 80 healthy adults. Researchers will assess the vaccine’s safety, tolerability and ability to produce an immune response. The trial will not determine whether the vaccine prevents infection because Phase 1 studies focus on early safety data. The Coalition for Epidemic Preparedness Innovations has committed up to $50 million for preclinical work, the trial and production of additional research doses.

    WHO recorded 3,605 confirmed cases and 1,587 deaths in DR Congo through July 30. At least 651 patients had recovered by that date. Updated figures cited by CEPI on August 4 placed infections above 3,800 and deaths above 1,700. Cases had reached 49 health zones across Ituri, North Kivu, South Kivu, Haut-Uélé and Tshopo provinces. Thirty-three health zones had reported recent infections, while Ituri accounted for 88% of confirmed cases.

    Outbreak exposes vaccine gap

    WHO declared the outbreak an international public health emergency on May 17. It is DR Congo’s 17th Ebola outbreak since scientists identified the virus in 1976. The current epidemic involves the Bundibugyo species, which previously caused outbreaks in Uganda and DR Congo. No approved vaccine or specific treatment currently targets this Ebola species. Licensed Ebola vaccines target Zaire ebolavirus, a different member of the virus family.

    Bundibugyo ebolavirus spreads through direct contact with infected blood, body fluids, organs or contaminated materials. Public health teams have expanded laboratory testing, contact tracing, clinical care and infection prevention measures. Officials had identified 17,863 contacts for monitoring through July 30. WHO also reported 151 confirmed infections among health workers, including 44 deaths. Conflict, displacement and attacks on health facilities have disrupted access and response work in several affected areas.

    Multiple candidates enter testing

    The Moderna study follows the launch of a separate Phase 1 vaccine trial by the University of Oxford. Oxford researchers vaccinated their first volunteer on July 24 with a candidate using the ChAdOx1 platform. The Serum Institute of India manufactured the Oxford vaccine and produced about 620,000 stockpiled doses. It also supplied 4,000 investigational doses for clinical testing. CEPI supports both programs as part of its Bundibugyo vaccine development portfolio.

    Moderna’s mRNA-1469 candidate uses the same underlying technology platform as the company’s COVID-19 vaccine. CEPI is also backing two candidates based on recombinant vesicular stomatitis virus technology. IAVI developed one candidate, with Hilleman Laboratories leading manufacturing, while Public Health Vaccines developed the other. None of the candidates has received regulatory approval for public use. WHO says surveillance, rapid diagnosis, patient care, safe burials and community engagement remain central to controlling the outbreak.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

    October 28, 2026

    Malaria kills 22 in Namibia’s Zambezi Region as cases rise

    October 26, 2026
    Latest News
    Business

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    – The South African rand is caught between rising inflation and weak economic growth as the country faces a week of key decisions on prices and interest rates. Higher petrol prices pushed consumer inflation sharply higher in October, while soft

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026

    Etihad plans seven weekly Calgary flights as demand grows

    November 17, 2026

    Sheikh Mohamed receives Venezuela’s Delcy Rodríguez in Abu Dhabi

    November 17, 2026

    Sheikh Mohamed and Ramos-Horta talk trade, energy and ASEAN

    November 16, 2026
    © 2026 Egypt News Hub | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.